Deciphera Pharmaceuticals Inc Stock News

Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into furt

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Ste

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.26% and 2.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for

Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Ste

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Jennifer Larson - Senior Vice President, Finance and Investor Relations S

Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.